Literature DB >> 8393732

Evidence that TGF-beta can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms.

F E Fox1, H C Ford, R Douglas, S Cherian, P C Nowell.   

Abstract

Transforming growth factor-beta (TGF-beta) has been documented as having an inhibitory effect on the proliferation and growth of human T-lymphocytes. We examined the relative contribution of both exogenous and endogenous TGF-beta to this inhibitory action. Purified human peripheral blood T-cells were cultured with Con A (0.2 microgram/ml), washed with methyl mannopyranoside, and then cultured in rIL-2 (5 U/ml) with or without TGF-beta (80 pM). Proliferation, as measured by uptake of tritiated thymidine at 72 hr, was inhibited by added active TGF-beta. Addition of neutralizing anti-TGF-beta antibodies at the initiation of culture abrogated the antiproliferative effects of TGF-beta. A mink lung cell bioassay was used to measure endogenous TGF-beta production by the T-cells following transient acidification of the supernatants to activate latent TGF-beta. T-lymphocytes cultured with rIL-2 alone produced low levels of TGF-beta, first detectable at 72 hr. The addition of (active) TGF-beta to these cultures resulted in earlier and higher levels of endogenously produced latent TGF-beta protein. This was reflected at the mRNA level as well. The exogenously added active TGF-beta appeared to be depleted during the culture period, presumably by the activated T-cells, which exhibited elevated levels of types I, II, and III TGF-beta receptors. The increase in TGF-beta protein levels was due to endogenous TGF-beta synthesis and secretion as supported by a capture assay using 35S-labeled culture supernatants. These findings indicate that both paracrine and autocrine mechanisms are involved in the inhibitory effects of TGF-beta on the proliferation of normal human T-lymphocytes and suggest that other TGF-beta-producing cells can augment production of TGF-beta by activated T-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393732     DOI: 10.1006/cimm.1993.1177

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

Review 1.  TGF-beta-mediated control of allergen-specific T-cell responses.

Authors:  Carsten B Schmidt-Weber; Steffen Kunzmann; Kurt Blaser
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

2.  Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro.

Authors:  T Kanto; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; N Hayashi; M Hori
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

3.  Enforced mesenchymal stem cell tissue colonization counteracts immunopathology.

Authors:  David García-Bernal; Miguel Blanquer; Carlos M Martínez; Ana I García-Guillén; Ana M García-Hernández; M Carmen Algueró; Rosa Yáñez; María L Lamana; Jose M Moraleda; Robert Sackstein
Journal:  NPJ Regen Med       Date:  2022-10-19

4.  Altered IL-10 levels in trauma patients' M phi and T lymphocytes.

Authors:  C L Miller-Graziano; A K De; K Kodys
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

5.  Transforming growth factor-beta 1 (TGF-beta1)-mediated inhibition of glial cell proliferation and down-regulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-gamma (IFN-gamma).

Authors:  B G Xiao; G X Zhang; C G Ma; H Link
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

6.  TGF-β suppresses RasGRP1 expression and supports regulatory T cell resistance against p53-induced CD28-dependent T-cell apoptosis.

Authors:  Mariko Takami; Christina Cunha; Shinichiro Motohashi; Toshinori Nakayama; Makio Iwashima
Journal:  Eur J Immunol       Date:  2018-10-24       Impact factor: 5.532

7.  Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.

Authors:  G Bellone; A Turletti; E Artusio; K Mareschi; A Carbone; D Tibaudi; A Robecchi; G Emanuelli; U Rodeck
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 8.  The human thymus during aging.

Authors:  B F Haynes; G D Sempowski; A F Wells; L P Hale
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

9.  Cellular responses to Plasmodium falciparum erythrocyte membrane protein-1: use of relatively conserved synthetic peptide pools to determine CD4 T cell responses in malaria-exposed individuals in Benin, West Africa.

Authors:  Latifu A Sanni; Catherine E M Allsopp; Lieke Reubsaet; Ambaliou Sanni; Chris Newbold; Virander S Chauhan; Jean Langhorne
Journal:  Malar J       Date:  2002-04-26       Impact factor: 2.979

10.  Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide.

Authors:  Xin Chen; Lalage M Wakefield; Joost J Oppenheim
Journal:  Oncoimmunology       Date:  2014-04-16       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.